Goldman, Van Nuys and colleagues propose a three-part pricing (TPP) model that ties prices to value but removes the need to monitor efficacy in each patient. The model creates a tiered system, with prices varying over fixed time intervals.
Pharmaceutical Pricing and Medical Innovation
Other featured articles
Trump Might Actually Lower Drug Prices
Dana Goldman and Anupam Jena write in The Washington Post that the Trump administration may succeed in lowering drug prices by fostering competition and innovation, and possibly ending kickbacks in the supply chain.
The Bigger Message Behind Amgen’s Decision to Slash Cost of its Repatha Cholesterol Drug
Drug companies look to haggle less and sell more, and that could cost Express Scripts, CVS Health and UnitedHealth writes Goldman in MarketWatch.
White House Signs Bills Banning Gag Clauses, Schaeffer Center Research Pivotal in Discussion
Schaeffer Center report found 23 percent of private claims analyzed involved a copayment that exceeded the insurer’s cost of the drug.
About this section
High pharmaceutical prices may garner headlines, but innovation must be appropriately incentivized to help solve healthcare’s intractable challenges. The Schaeffer Center connects industry, the academy and government to support the scientific and technological creativity that saves and improves lives — and spurs economic growth.